Andere Sprachen BeOne Medicines AG

Aktien

A1437N

US07725L1026

ONC

Biotechnologie

Realtime-Estimate Cboe BZX Andere Börsenplätze 21:22:24 12.02.2026			% 5 Tage	Veränd. 1. Jan.
347,54 ^USD	-1,06 %		+0,27 %	+14,53 %

28.01.	InSysBio gibt Verlängerung der Zusammenarbeit mit BeOne Medicines bekannt	CI
15.01.	BeOne-CEO über Geschäftsstrategie und Aussichten der Biotechnologiebranche	MT

Andere Sprachen

11.02.	BeOne Medicines annoncera le 26 février ses résultats financiers du quatrième trimestre et de l'exercice 2025
11.02.	BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26
28.01.	InSysBio Announces the Extension of Collaboration with BeOne Medicines
15.01.	BeOne CEO on Business Strategy, Biotech Outlook
13.01.	BeOne Medicines destaca su liderazgo global en oncología en la 44.a Conferencia Anual de Salud de J.P. Morgan
13.01.	BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
07.01.	ZIIHERA más TEVIMBRA y quimioterapia: un posible nuevo estándar para primera línea en adenocarcinoma gástrico y esofágico avanzado HER2+
07.01.	ZIIHERA plus TEVIMBRA et chimiothérapie : un nouveau traitement potentiel de première intention contre l'adénocarcinome gastro-œsophagien avancé avec mutation HER2+
06.01.	BeOne Medicines Ltd. Announces Full Results from the Phase 3 Herizon-Gea-01 Trial Evaluating Ziihera
06.01.	Zymeworks Inc. Announces Positive Efficacy and Safety Results from the Phase 3 HERIZON-GEA-01 Trial Evaluating Ziihera
06.01.	ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA
06.01.	BeOne Medicines : rsquo; Novel BCL2 Inhibitor, Sonrotoclax, Achieves First-in-World Approval in R/R MCL and R/R CLL/SLL
23.12.	Health Canada Approves Tevimbra® (Tislelizumab for Injection) in Combination with Gemcitabine and Cisplatin for the First-Line Treatment of Adult Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma
23.12.	Senhwa Biosciences, Inc Outlines Continued Progress Across Its Ai-Enabled Drug Development Platform
23.12.	BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
19.12.	Beone Medicines Ag Announces Termination of Credit Facility and Repayment Using Proceeds from Borrowings
18.12.	BeOne Medicines recibió la designación de aprobación acelerada por parte de la FDA de los Estados Unidos para BGB-B2033 como tratamiento para el carcinoma hepatocelular
18.12.	BeOne Medicines Ltd. obtient la désignation « Fast Track » de la part de la FDA américaine pour le BGB-B2033 dans le traitement du carcinome hépatocellulaire
18.12.	BeOne Medicines Says US FDA's Fast Track Designation Received for Hepatocellular Carcinoma Treatment
18.12.	BeOne Medicines Ltd. Grants U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
18.12.	BeOne Medicines Ltd. Appoints Lai Wang as President, Global Head of Research and Development, Effective January 1, 2026
18.12.	BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
12.12.	Amgen Inc. Announces FDA Approval Of UPLIZNA For Adults With Generalized Myasthenia Gravis
11.12.	Senhwa Biosciences, Inc. and BeOne Medicines Announces Clinical Supply Agreement to Address the Challenge of Cold Tumors
10.12.	BeOne Medicines' Brukinsa Poised for Growth Through 2026 Despite Rising BTK Competition, RBC Says

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen MarketScreener Artikel MarketScreener Analysen Trading-Ideen

Filter

Schlagzeilen

BeOne-CEO über Geschäftsstrategie und Aussichten der Biotechnologiebranche

Am 15. Januar 2026 um 17:41 Uhr